Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
The views and opinions expressed in the following PowerPoint slides are
those of the individual presenter and should not be attributed to Drug
Information Association, Inc. (“DIA”), its directors, officers, employees,
volunteers, members, chapters, councils, Special Interest Area
Communities or affiliates, or any organization with which the presenter is
employed or affiliated.
These PowerPoint slides are the intellectual property of the individual
presenter and are protected under the copyright laws of the United States of
America and other countries. Used by permission. All rights reserved. Drug
Information Association, DIA and DIA logo are registered trademarks or
trademarks of Drug Information Association Inc. All other trademarks are
the property of their respective owners.
2www.diahome.orgDrug Information Association
• Safety of drugs that are marketed in the US has always
been a high-priority activity at the FDA
• However, for many years Clinical Trials (CT) were
designed to determine drug efficacy – rarely had pre-
specified safety endpoints
• In addition to Safety information from CT’s, reviewers
analyze– Non-clinical data
– Clinical Pharmacology studies
– Same drug for other indications
– Other drugs in class
– Medical literature
– Post-Marketing experience, if available
– Combining data from multiple studies
Drug Safety – FDA Experience
Drug Information Association www.diahome.org 3
• 1906 Pure Food & Drugs Act prohibits interstate commerce
in misbranded and adulterated foods, drinks and drugs
• 1938 The Federal Food Drug & Cosmetic Act (FDC)
passed - Requires new drugs to be shown safe before
marketing. This started a new system of drug regulation.
• 1962 Kefauver-Harris Drug Amendments passed to ensure
drug efficacy. Manufacturers now required to study the
effectiveness of drugs before marketing them. However the
regulations for safety assessments did not change.
Drug Safety Regulation in the US
Drug Information Association4
www.diahome.org
5
Prescription Drug User Fee Act (PDUFA)
• In 1992, Congress passed PDUFA legislation, which
authorized FDA to collect fees from companies that
produce and market drug and biological products.
– These fees could not be used by FDA for safety functions
• 2002 Congress passed PDUFA III and Risk
Management requirements
– allowed PDUFA funds to be used for Postmarketing Safety
– Focused attention on Risk Management and Risk
Communication
• 2005 FDA risk management guidelines finalized
Drug Information Association www.diahome.org
6
Drug Safety Regulation in the US
• 2006 US Institute of Medicine Report on FDA & Drug
Safety was critical of the current system & proposes:
– Labeling requirements and advertising limits for new drugs
– Clarified authority and additional enforcement tools for FDA
– Clarification of the FDA’s role in gathering and communicating
additional information on marketed products’ risks and benefits,
• 2007 PDUFA IV & FDAAA
– Introduced the concept of Risk Evaluation and Mitigation
Strategies (REMS)
– Mandatory registration of clinical trial results to facilitate public
access to drug safety information (www.clinicaltrials.gov)
– An increased role for the FDA’s drug safety staff and a large
boost in funding and staffing for the agency”
• 2012 PDUFA V & FDASIADrug Information Association www.diahome.org
• Clinical trials provide a controlled environment
– Strict inclusion/exclusion criteria
– Investigators are obliged to report adverse events
• Known denominator for patient exposure
• Data collected on standardized form
• Follow-up information is generally accessible
• All reports are medically confirmed
• Investigators are trained in collection and reporting of
adverse events
– Immediately notify sponsor of all ‘serious’ adverse
events for possible expedited reporting
Drug Safety in Clinical Trials (CT)
(Before Product Is Marketed)
7Drug Information Association www.diahome.org
• Collect adverse events (‘serious’ and ‘non-serious’) whether or
not thought related to study medication
• Analysis of adverse events for relation to protocol and study
medication and possible safety concerns
• For AEs that seem drug related additional analyses should be
done:
– Explorations for dose dependency.
– Time to onset.
– Adaptation & tolerance to certain AEs (e.g. nausea, somnolence).
– Drug-demographic, drug-disease, and drug-drug interactions.
– Analysis of the AE by severity.
• Identify patients who might be susceptible to safety concerns
• Consequence evaluation and analysis
Essential Pre-Marketing Pharmacovigilance
Activities
8Drug Information Association www.diahome.org
• Size of CT database is limited (3,000-10,000 subjects)
• Restricted population– Often not special groups (e.g., children, elderly, females)
• Narrow indications that often do not address actual practice– Inclusion criteria often require specificity of diagnosis
– Co-morbid conditions are often excluded
– Concomitant medications are often limited
• Short duration (weeks - 3 years)– Latent & long term safety effects not directly measured
• Surrogates often used instead of the true ‘outcome of interest’
• Need to develop improved ways to overcome shortcomings of CT after marketing– Surveillance ADRs, epidemiology, phase IV studies
Limitations of Clinical Trials
(Before a Product Is Marketed)
9Drug Information Association www.diahome.org
FDA reviewers look at all the available data:– To identify and closely examine serious adverse events that suggest,
or could suggest, important problems with a drug-- specifically, adverse
reactions severe enough to prevent its use altogether, to limit its use, or
require special risk management efforts
– To identify and estimate the frequency of the common (usually
nonserious) adverse events that are, or may be, causally related to
the use of the drug;
– To evaluate the adequacy of the data available to support the safety
analysis and to identify the limitations of those data. At a minimum, this
includes assessments of whether the extent of exposure at relevant
doses is adequate
– To identify unresolved safety concerns that will need attention prior
to approval or that should be assessed in the postmarketing period,
including such concerns as the absence of data from high-risk
populations or potential interactions
Review of New Drug Applications
10Drug Information Association www.diahome.org
FDA reviewers will also look for ways to:– Identify factors that predict the occurrence of ADRs, including
patient-related factors (e.g., age, gender, ethnicity, race, target illness,
abnormalities of renal or hepatic function, co-morbid illnesses, genetic
characteristics, such as metabolic status, environment) and drug-related
factors (e.g., dose, plasma level, duration of exposure, concomitant
medication)
– Identify, where possible, ways to avoid ADRs (dosing, monitoring) and
ways to manage them when they occur
– For a drug that is to be approved, provide a comprehensive evaluation
of risk information adequate to support a factual and sufficient
summary of the risk information in labeling.
Review of New Drug Applications
11Drug Information Association www.diahome.org
• Rofecoxib is a nonsteroidal anti-inflammatory drug
(NSAID). It was approved by the Food and Drug
Administration (FDA) on May 20, 1999, and was
marketed under the brand name Vioxx.
– ~5000 patients; exposure > minimum ICH
– Safe and effective for intended indications
• up to 25mg for Osteo-arthritis
• 50mg for acute pain [5 days])
• Safety profile appeared similar to other NSAIDs
– Caveats - 75% of subjects were female with OA
- few used low dose aspirin
- NSAID comparators: ibuprofen & diclofenac
Vioxx Approval
Drug Information Association www.diahome.org 12
• At the time of approval, the VIGOR study was already
underway. It’s purpose was to support removal of
Gastrointestinal (GI) WARNING required for all NSAIDS
– Rofecoxib quickly gained widespread acceptance among
physicians treating patients with arthritis and other
conditions causing chronic or acute pain.
• October 2002, sponsor proposed pooled analysis of CV/T
events in 3 double-blind, placebo-controlled studies – 25,000 patients followed for 6 years, CV adjudication
– Vioxx 25 mg/day vs. placebo
• VIGOR study presented at FDA Advisory Committee
meeting, which recommended further evaluation of CV
safety in completed and ongoing trials
Vioxx Approval
Drug Information Association www.diahome.org 13
• On September 30, 2004, Merck withdrew rofecoxib from
the market upon 1-year interim results of the APPROVe
study because of concerns about increased risk of heart
attack and stroke associated with long-term, high-
dosage use.
• Class labeling for potential increased risk of CV/T events added to all NSAIDs
• Called attention into Drug Safety evaluation, monitoring and risk management ---- > FDAAA (2007)
Vioxx Conclusions
Drug Information Association www.diahome.org 14
• Gave the FDA new authority, including the ability to
require applicants to develop and comply with Risk
Evaluation and Mitigation Strategies (REMS) if
necessary to ensure that the benefits of the drug
outweigh its risks
• A REMS is a strategy to handle a risk (identified or
potential) associated with a product
– It allows patients to use the product but under certain conditions
and surveillance
– beyond routine professional labeling to ensure the benefits of a
drug outweigh the risks
• It is enforceable and is included with the approval letter
FDA Amendments Act - 2007
15 www.diahome.org
REMS
16
• A Risk Evaluation and Mitigation Strategy (REMS) applies
in the US
• Concept is similar to the EU Risk Minimization Plan
• FDA gained authority to require REMS under legislation (FDAAA)
enacted in 2007
• REMS may be required on approval of the drug to ensure
that benefits outweigh risks or at any time after approval if
new information raises a safety concern
• Draft Guidance on REMS issued in 2009
• As of July 2013, there are 72 REMS. 66 individual drugs 6
shared system REMS including 84 applications (NDA and
ANDA)
www.diahome.org
REMS
• A REMS may include:
– A Medication Guide (MedGuide or patient package insert)
– A communication to Health Care Providers
– Elements to Assure Safe Use (ETASU), e.g.,
• Special training or certification for HCPs who prescribe or
dispense
• Dispensing only in certain settings (e.g., in a hospital) or with
evidence of safe use conditions (e.g., lab test)
• Monitoring or registration of each patient using the medicine
• A REMS must always include a timetable and metrics for
assessment of its effectiveness
– At a minimum at 1.5 years, 3 years, and in the 7th year
17 www.diahome.org
• Rosiglitazone (trade name Avandia), is an anti-diabetic drug
developed by GlaxoSmithKline and approved in the US in
May of 1999.
– The sponsor agreed to a Phase 4 commitment to conduct a long-term
(4-year) safety and efficacy study (titled AADOPT@ study) of Avandia
compared to metformin in patients with type 2 diabetes mellitus. Among
other endpoints, the study was to measure the incidence of
cardiovascular events.
– The results of the AADOPT study shows Rosiglitazone appears to
increase the risk of heart attacks and death.
– Some FDA reviewers recommended rosiglitazone be taken off the
market, but an FDA Advisory panel disagreed, and it remains available
in the U.S., subject to significant restrictions.
– In Europe, the European Medicines Agency (EMA) recommended in
September 2010 that the drug be suspended from the European
market. It has also been removed from the market in many other
countries.
Avandia
Drug Information Association www.diahome.org 18
• The REMS, with ETASU, finalized in November of 2011,
requires:– Healthcare providers who prescribe rosiglitazone-containing medicines
for outpatient or long-term care use are specially certified.
– Rosiglitazone will be dispensed only by specially certified pharmacies.
– Rosiglitazone will only be dispensed to patients with evidence or other documentation of safe-use conditions.
– GSK must maintain a secure , validated, interactive, web-database of all enrolled patients. The database allows certified prescribers to enroll themselves and to enroll patients. Pharmacies can also access the database to verify patient and prescriber enrollment status.
• The Rosiglitazone REMS is quite extensive, and can be found at: http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm255624.pdf
Avandia REMS
Drug Information Association www.diahome.org 19
• In 2011, FDA began an initiative designed
– to evaluate how we have been implementing our REMS
authority.
– to determine how to design REMS that can be better integrated
into the existing and evolving healthcare system.
• FDA is tasked to Develop:
– Specific Criteria for determining when a REMS is required.
– Strategies for designing REMS, including standardization, so
they can be efficiently integrated into the existing and evolving
healthcare system.
– An evidence-based approach to measuring the effectiveness of
REMS.
• FDA gathered preliminary input from stakeholders
REMS Integration Initiative: Overview
Drug Information Association www.diahome.org 20
• The REMS Integration Steering Committee
(RISC) was established to oversee the REMS
Integration Initiative.
– REMS Policy Workgroup• Develop principles for how to apply the statutory criteria to
determine whether a REMS is necessary
– REMS Design and Standardization Workgroup • Develop an analytically rigorous approach to design of a REMS
– REMS Evaluation Workgroup • Develop a consistent and evidence-based approach for assessing
the effectiveness of REMS programs and the burden on healthcare
delivery systems
REMS Integration Steering Committee
Drug Information Association www.diahome.org 21
What Standardization Looks Like
Minimize Variation Improve Quality
REMS Design REMS that address similar risks with similar stakeholders / settings use similar tools
Rigorous and evidence-based approaches are used to set REMS goals and requirements
REMS Tools REMS use similar tools drawn from a standardized REMS “toolkit”.
REMS tools are informed by the latest science, stakeholder feedback, and established “best practices”.
(c) 2013 DIA, Inc. All rights reserved 22
• Information about the REMS Integration
Initiative is available on the FDA website
(http://www.fda.gov)
• Thank you for your participation.
Drug Information Association www.diahome.org 23